Log In
BCIQ
Print this Print this
 

TD101

  Manage Alerts
Collapse Summary General Information
Company TransDerm Inc.
DescriptionShort interfering RNA (siRNA) that targets the N171K mutant form of the keratin 6A (KRT6A; CK6A) gene
Molecular Target Keratin 6A (KRT6A) (CK6A)
Mechanism of Action 
Therapeutic ModalityNucleic acid: Linear RNA: siRNA
Latest Stage of DevelopmentPhase I
Standard Indication Dermatology (unspecified)
Indication DetailsTreat pachyonychia congenita
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today